Deep Vein Thrombosis Clinical Trial
Official title:
Advanced Diagnostic Management of Suspected Recurrent Ipsilateral Deep Vein Thrombosis of the Leg With Magnetic Resonance Direct Thrombus Imaging
The Theia-study is a prospective, multicenter, single-arm management (cohort) study.
Consecutive patients with clinically suspected acute, recurrent, ipsilateral, proximal deep
vein thrombosis (DVT) of the leg, who fulfil all the inclusion criteria and meet none of the
exclusion criteria, are eligible for inclusion and will be managed according to the result of
a magnetic resonance direct thrombus imaging (MRDTI) of the affected leg. The MRDTI is to be
performed and adjudicated within 24 hours of study inclusion. The final treatment decision
will be made based on this ruling of the MRDTI. In case of a positive MRDTI signal, patients
will be treated with therapeutically dosed anticoagulants or modified in patients with a
recurrent DVT on anticoagulant therapy. Patients with a negative MRDTI ruling will be left
untreated, or treatment will be remained unadjusted if they are on anticoagulant treatment at
inclusion. All patients with negative MRDTI will be subjected to a standardized compression
ultrasonography (CUS) within 48 hours after initial presentation. The latter CUS serves as a
reference test in case the patient returns with symptoms of ipsilateral recurrence in the
future, and will not be used for management decisions at baseline. The study flowchart can be
found in Appendix A.
All patients will be followed for three months for the occurrence of acute recurrent venous
thrombo-embolism (VTE). In case of suspected recurrent VTE, objective testing including
either computed tomography pulmonary angiography (CTPA) for PE or CUS for DVT will be
performed. Additionally, in case of a proven ipsilateral recurrent DVT during follow-up,
MRDTI will be repeated.
See below. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |